Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye ...

Roche, the parent company of Indianapolis-based Roche Diagnostics, said it received FDA clearance to sell a new test to help determine ... high blood pressure and diabetes.

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

Roche Holding said the U.S. Food and Drug Administration approved a test to identify patients with a specific type of breast cancer. The Swiss pharmaceutical company said the FDA backed a label ...

"Today we're proud to announce that we're joining the Roche family to help create an open digital diabetes ecosystem that revolves entirely around people with diabetes." The company says it will ...

“Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a potentially blinding diabetic eye condition,” said Levi Garraway, MD, PhD, Roche's ...

Roche announced that the US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss ...

“Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a potentially blinding diabetic eye condition,” said Levi Garraway, MD, PhD, Roche's Chief ...

The new trial investigated the role of the Pro version of the mySugr app, a digital diabetes logbook which Roche acquired along ... was specifically designed to test the effects of the app on ...

1 The Roche Diagnostics Tina-quant® Lipoprotein (a) Gen.2 Molarity assay is an in-vitro test measuring lipoprotein (a) in a person's bloodstream (serum and plasma), and will be broadly available ...